Citation: Gareth Morgan. Prophylactic aspirin and public[J]. AIMS Public Health, 2014, 1(1): 1-8. doi: 10.3934/publichealth.2013.1.1
[1] | Elwood, P. ; Longley, M. (2010) My health: whose responsibility?: A Jury decides. J Epidemiol Commun H 64: 761-764. doi: 10.1136/jech.2009.087767 |
[2] | Antithrombotic, T. (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849-1860. doi: 10.1016/S0140-6736(09)60503-1 |
[3] | Elwood, P. ; Morgan, G. ; Fone, D. et al. (2011) Aspirin use in a south-Wales county. Br J Cardiol 18: 238-240. |
[4] | Morgan, G. (2012) Rapid health impact assessment of aspirin promotion for the secondary prophylaxis of vascular events in Wales. Qual Prim Care 20: 299-301. |
[5] | Elwood, P. ; Gallagher, A. M. ; Duthie, G. G. et al. (2008) Aspirin, salicylates and cancer. Lancet373: 1301-1309. |
[6] | Rothwell, P. M; Wilson, M. ; Elwin, C. E. et al. (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376: 1741-1750. doi: 10.1016/S0140-6736(10)61543-7 |
[7] | Rothwell, P. M; Fowkes, F. G. R; Belch, J. F. F. et al. (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet377: 31-41. |
[8] | Burn, J. ; Gerdes, A. M. ; Macrae, F. et al. (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 RCT. Lancet 378: 281-287. |
[9] | Phillips, I. ; Langley, R. ; Gilbert, D. ; et al. (2013) Aspirin as a treatment for cancer. Clin Oncol (R Coll Radiol) 25: 333-335. doi: 10.1016/j.clon.2013.03.001 |
[10] | Morgan, G. ; Elwood, P. (2009) Could recommendations about aspirin prophylaxis enhance colorectal cancer screening programmes? Eur J Public Health 19: 576-577. doi: 10.1093/eurpub/ckp062 |
[11] | Morgan, G. (2009) Aspirin for the prevention of vascular events. Public Health 123: 787-788. doi: 10.1016/j.puhe.2009.10.007 |
[12] | Gorelick, P. B. ; Weisman, S. M. (2005) Risk of haemorrhagic stroke with aspirin use: an update. Stroke 36: 1801-1807. doi: 10.1161/01.STR.0000174189.81153.85 |
[13] | Hansson, L. ; Zanchetti, A. ; Carruthers, S. G. et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755-1762. |
[14] | Elwood, P. ; Morgan, G. ; Brown, G. ; et al. (2005) Aspirin for all over 50? For. British Medical Journal 330: 1440-1441. doi: 10.1136/bmj.330.7505.1440 |
[15] | Baigent, C. ; (2005) Aspirin for all over 50? Against. British Medical Journal 330: 1441-1442. |
[16] | Baron, J. A. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med348:891-899. |
[17] | Chan, A. T. ; Giconnucci, E. L. ; Schernhammer, E. S. et al. (2004) A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med 140: 157-166. doi: 10.7326/0003-4819-140-3-200402030-00006 |
[18] | Brenner, H. ; Tao, S. ; Haug, U. (2010) Low-dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA 304: 2513-2520. doi: 10.1001/jama.2010.1773 |
[19] | Ajani, U. A. ; Ford, E. S. ; Greenland, K. J. (2006) Aspirin use among US adults: Behavioural Risk Factor Surveillance System. Amer J Prev Med 30: 74-77. doi: 10.1016/j.amepre.2005.08.042 |
[20] | Sung, J. J. ; Lau, J. Y. ; Ching, J. Y. et al. (2010) Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 152: 1-9. doi: 10.7326/0003-4819-152-1-201001050-00179 |
[21] | US Preventive Services Task Force. (2009) Aspirin for the prevention of cardiovascular disease: US preventive services task force recommendation statement. Ann Intern Med 150: 396-404. doi: 10.7326/0003-4819-150-6-200903170-00008 |